Regentis Biomaterials Ltd. (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC® using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC®, which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
The approval marks a significant step for Regentis as it prepares to bring GelrinC® to market. The enhanced manufacturing process not only boosts yield but also improves safety and scalability, key factors for meeting potential demand. The company’s focus on a $3 billion U.S. market underscores the opportunity, as no off-the-shelf treatment is currently available for the approximately 470,000 annual cartilage knee repair cases in the U.S.
For business and technology leaders, this development highlights the convergence of advanced manufacturing techniques and regenerative medicine. The solvent-free process reduces environmental impact and occupational hazards, aligning with broader sustainability trends in manufacturing. The ability to produce five times more product from the same volume could lower costs and improve supply chain reliability, potentially making the treatment more accessible.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC® is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process.
For more information, visit the company’s newsroom at https://ibn.fm/RGNT.
